There are 38 papers on liver failure in aging research: 18 observational studies in people, 9 in animals, 8 reviews.
9 new papers in 30 daysSee all 119 papers on liver failure
“hepatic failure (HepF) and cardiac arrest/ventricular fibrillation (CA/VF) emerged as key ADE signals after atorvastatin initiation.”
- Humans18
- Animals9
Interventions
1Atorvastatin
upin humans1
1 study
Atorvastatin
upin humans1
Atorvastatin is linked with liver failure in humans (secondary stroke prevention).
“developed hyperacute hepatic failure within 24 hours of initiating atorvastatin 80 mg for secondary stroke prevention”
Humanssecondary stroke preventionliver80 mgwithin 24 hoursmales
Statin-Induced Hyper-Acute Reversible Liver Failure: A Case Report
Cureus
Associations
6Protein risk score
upin silico1
1 study
Protein risk score
upin silico1
Protein risk score predicts liver failure in silico (C-index = 0.84).
“and liver failure (C-index = 0.84) in a healthy population without liver diseases at baseline.”
In silico
Diabetes, obesity & metabolism
Psychosocial stressors
upin humans1RR 2.24
1 study
Psychosocial stressors
upin humans1RR 2.24
Psychosocial stressors are linked with a higher risk of liver failure in humans (RR = 2.24, p = 0.002).
“and liver failure (RR = 2.24, p = 0.002).”
Humans5-year follow-upfemales
AHA Scientific Sessions 2025 abstract
Liver age gap
upin humans1HR 2.13
1 study
Liver age gap
upin humans1HR 2.13
Liver age gap is linked with a higher risk of liver failure in humans (HR 2.13 (95% CI 1.41-3.22) per SD increment).
“liver failure (hazard ratio [HR] per SD increment in the organ age gap 2·13 [95% CI 1·41-3·22])”
Humans20 yearsn = 6,235
The Lancet. Digital health
Atorvastatin
upin humans1
1 study
Atorvastatin
upin humans1
Atorvastatin is linked with a higher risk of liver failure in humans (atorvastatin initiation).
“hepatic failure (HepF) and cardiac arrest/ventricular fibrillation (CA/VF) emerged as key ADE signals after atorvastatin initiation.”
Humansatorvastatin initiationn = 690,004
Preprint
Modified Frailty Index
upin humans1
1 study
Modified Frailty Index
upin humans1
Modified Frailty Index is linked with a higher risk of liver failure in humans (5.4% vs 4.1%; p < 0.001).
“Frail patients experienced higher incidence of post-hepatectomy liver failure (5.4% vs 4.1% for non-frail; p < 0.001)”
Humansn = 24,150
The impact of minimally invasive surgery and frailty on post-hepatectomy outcomes
HPB : the official journal of the International Hepato Pancreato Biliary Association
Somatic cell cloning
upin mice1
1 study
Somatic cell cloning
upin mice1
Somatic cell cloning raises the risk of liver failure in mice cloned from somatic cells.
“most likely due to severe pneumonia and hepatic failure”
Animalsin mice cloned from somatic cells
Early death of mice cloned from somatic cells
Nature genetics
Trial sponsors
Company1 trialPhase 443 people
Asahi Kasei Therapeutics Corporation
Company2 trialsPhase 2117 people
Company2 trialsPhase 2117 people
Company1 trialPhase 2148 people
Company1 trialPhase 176 people
2 trialsPhase 4210 people
University Hospital, Basel, Switzerland
1 trialPhase 4113 people
The First Affiliated Hospital with Nanjing Medical University
1 trialPhase 430 people
Funding
11 grants since 2017Japan Society for the Promotion of Science¥34.7MNational Institute of Allergy and Infectious Diseases$3MNational Institute of Diabetes and Digestive and Kidney Diseases$46.4K
Induced pluripotent stem cell derived hepatocytes for liver failure (iPUSH for LIFE)
UKRI | Medical Research CouncilImperial College of Science Technology and Medicine£1.3M2026–2028
Natural Science Foundation of Hunan ProvinceCentral South University2026
Senescent hepatocytes mediate reprogramming of immune cells in acute liver failure
National Institute of Diabetes and Digestive and Kidney DiseasesUniversity of Kansas Medical Center$10.4K2023–2024
Novel regenerative therapy for liver failure with skeletal myoblast cell sheet transplantation
Japan Society for the Promotion of ScienceThe University of Osaka¥4.2M2022–2025
Japan Society for the Promotion of ScienceKyushu University¥4.2M2022–2025
Validation of mesenchymal stem cells and senolytics for acute on chronic liver failure
Japan Society for the Promotion of ScienceNiigata University¥4.4M2021–2025
Hepatocyte xenografts for treatment of acute liver failure
National Institute of Allergy and Infectious DiseasesUniversity of Pittsburgh at Pittsburgh$1M2016–2022
National Institute for Health ResearchUniversity College London£1.7M2018–2023
Japan Society for the Promotion of ScienceUniversity of Tsukuba¥17.3M2018–2022
The new method for the liver failure using the hybrid transplantation of the liver and Muse cells
Japan Society for the Promotion of ScienceTohoku University¥4.7M2017–2020
Contains public sector information licensed under the Open Government Licence v3.0.